TriangleNCT04682405 · OUTCOME
Median Daily Dose of Anti-diarrheal Medications
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- number of doses in one day
- Interval / dispersion
- Full Range
- Time frame
- Through date of discharge (up to be 18 days)
What was measured
This is defined as the number of doses of anti-diarrheal medications, such as loperamide or lomotil, that participants took daily.
Analysis population: The number of participants analyzed at each time point may differ from the overall number of participants analyzed because the data was not collected. One patient in the placebo + standard of care melphalan arm was not evaluable for the outcome measure.
Groups in this outcome
Uproleselan + Standard of Care Melphalan
Patients will receive six doses of Uproleselan intravenously. The doses will begin the evening of Day -3 and continue every 12 hours through the morning of Day 0, prior to hematopoietic stem cell transplant (auto-HCT). On the evening of Day -2, patients also receive one dose of standard of care Melphalan intravenously.
Placebo + Standard of Care Melphalan
Patients will receive six doses of placebo intravenously. The doses will begin the evening of Day -3 and continue every 12 hours through the morning of Day 0, prior to hematopoietic stem cell transplant (auto-HCT). On the evening of Day -2, patients also receive one dose of standard of care Melphalan intravenously.
| Group | Source count |
|---|---|
| Uproleselan + Standard of Care Melphalan | 23 |
| Placebo + Standard of Care Melphalan | 21 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Uproleselan + Standard of Care Melphalan | 2.20 | Not reported | 1.00 | 4.33 | Not reported |
| Placebo + Standard of Care Melphalan | 2.00 | Not reported | 1.00 | 5.50 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 1.00
- upper Limit
- 4.33
- value
- 2.20
- group Id
- OG001
- lower Limit
- 1.00
- upper Limit
- 5.50
- value
- 2.00
- denoms
- counts
- group Id
- OG000
- value
- 23
- group Id
- OG001
- value
- 21
- units
- Participants
- description
- This is defined as the number of doses of anti-diarrheal medications, such as loperamide or lomotil, that participants took daily.
- dispersion Type
- Full Range
- groups
- description
- Patients will receive six doses of Uproleselan intravenously. The doses will begin the evening of Day -3 and continue every 12 hours through the morning of Day 0, prior to hematopoietic stem cell transplant (auto-HCT). On the evening of Day -2, patients also receive one dose of standard of care Melphalan intravenously.
- id
- OG000
- title
- Uproleselan + Standard of Care Melphalan
- description
- Patients will receive six doses of placebo intravenously. The doses will begin the evening of Day -3 and continue every 12 hours through the morning of Day 0, prior to hematopoietic stem cell transplant (auto-HCT). On the evening of Day -2, patients also receive one dose of standard of care Melphalan intravenously.
- id
- OG001
- title
- Placebo + Standard of Care Melphalan
- param Type
- MEDIAN
- population Description
- The number of participants analyzed at each time point may differ from the overall number of participants analyzed because the data was not collected. One patient in the placebo + standard of care melphalan arm was not evaluable for the outcome measure.
- reporting Status
- POSTED
- time Frame
- Through date of discharge (up to be 18 days)
- title
- Median Daily Dose of Anti-diarrheal Medications
- type
- SECONDARY
- unit Of Measure
- number of doses in one day
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice